Related Experiment Video
Updated: Apr 17, 2026
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
[Moving activity and wakefulness-sleep cycle changes in a mouse MPTP model of Parkinson's disease]
Abstract:
A group of mice with preliminary implanted (under general anesthesia) electrodes for cortical EEG and nuchal EMG was subjected to continuous baseline 24-hr video and digital polysomnographic recording with the 12/12 light/dark schedule, and then injected subcutaneously with 24 or 48 mg/kg of MPTP toxin or (the control group) saline. The recordings were continued for 2 weeks more. A significant increase in activity and the waking percentage as well as decrease in REM sleep and NREM sleep (tendency) during the dark period as compared to the baseline and control recordings was found. The effect was seen just on the 7th day following MPTP administration and became significant by the 14th day. The effect was more pronounced after 48 mg/kg injection than after 24. There were no changes during the light period. Morphological control revealed a 70% and 35% decreases in the amount of tyrosine hydroxylase positive neurons in substancia nigra/pars compacta after 48 and 24 mg/kg of MPTP, respectively, as compared to the saline group.
Insights
MPTP toxin significantly disrupted mouse sleep patterns, increasing wakefulness and reducing REM sleep during dark periods. These sleep changes correlated with a loss of dopamine-producing neurons in the substantia nigra.
Area of Science:
- Neuroscience
- Sleep Science
- Toxicology
Context:
- The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxin is a well-established model for inducing Parkinsonism in rodents.
- Sleep disturbances are common in neurodegenerative diseases, but the direct impact of MPTP on sleep architecture requires further elucidation.
Purpose:
- To investigate the effects of MPTP administration on sleep patterns and polysomnography in mice.
- To correlate observed sleep changes with neurochemical alterations in the substantia nigra.
Summary:
- Mice treated with MPTP (24 or 48 mg/kg) exhibited increased wakefulness and reduced REM sleep during the dark phase, with effects becoming significant by day 14 post-injection.
- These behavioral changes were dose-dependent and accompanied by a significant reduction in tyrosine hydroxylase-positive neurons in the substantia nigra/pars compacta.
- No significant alterations in sleep were observed during the light period.
Impact:
- This study provides crucial insights into the neurotoxic effects of MPTP on sleep-wake regulation, relevant for Parkinson's disease research.
- The findings highlight the sensitivity of sleep architecture to dopaminergic neurodegeneration, offering potential biomarkers for disease progression.
